Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL101 in Notch-Activated TNBC
NCT04461600Phase 2Terminated
- Sponsor
- Ayala Pharmaceuticals, Inc.
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of osugacestat in triple-negative breast cancer (TNBC), sponsored by Ayala Pharmaceuticals, Inc. Primary endpoint: Overall Response Rate at 12 months. Started Aug 2020; status: terminated.
02
Drugs
osugacestat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04461600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04461600.